Floatz logo

Irinotecan

ATRT Recurrent

Medical University of ViennaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the ATRT Recurrent cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2B
Thalidomide
Medical University of Vienna
Phase 2CCC
Cyclophosphamide
Medical University of Vienna
Phase 2CCC
Fenofibric Acid
Medical University of Vienna
Phase 2CCC
ETOPOSIDE
Medical University of Vienna
Phase 2CCC

View all 39 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →